

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number  
**WO 02/086114 A1**

(51) International Patent Classification<sup>7</sup>: C12N 9/02,  
A21D 8/04, C12P 7/64, C12N 15/63, C11D 3/386

(21) International Application Number: PCT/DK02/00251

(22) International Filing Date: 18 April 2002 (18.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 00631 20 April 2001 (20.04.2001) DK

(71) Applicant (for all designated States except US):  
NOVOZYMES A/S [DK/DK]; Krogshoejvej 36, DK-2880  
Bagsvaerd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SUGIO, Akiko  
[JP/US]; 1604 Hillcrest drive Apt. U-21, Manhattan, KS  
66502 (US). TAKAGI, Shinobu [JP/JP]; Maehara-nishi  
1-31-1-708, Funabashi, Chiba 274-0825 (JP).

(74) Common Representative: NOVOZYMES A/S; Patents,  
Krogshoejvej 36, DK-2880 Bagsvaerd (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: LIPOXYGENASE

(57) Abstract: The inventors have found a novel fungal lipoxygenase from *Magnaporthe salvinii* and determined its sequence. They have sequenced the gene and cloned it into *E. coli* and deposited the clone. Oligonucleotide probes based on the sequence information are useful for screening a eukaryotic library to obtain a lipoxygenase. The lipoxygenase is useful in baking and in a detergent.



WO 02/086114 A1

## LIPOXYGENASE

### FIELD OF THE INVENTION

The present invention relates to a lipoxygenase and a polynucleotide encoding it.

### 5 BACKGROUND OF THE INVENTION

Lipoxygenase (EC 1.13.11.12) is an enzyme that catalyzes the oxygenation of poly-unsaturated fatty acids such as linoleic acid, linolenic acid and arachidonic acid, which contain a *cis,cis*-1,4-pentadiene unit and produces hydroperoxides of these fatty acids. The enzyme is widely distributed in plants and animals. A number of lipoxygenase genes have been isolated  
10 from various plant and mammalian sources.

On the other hand, only a limited number of microbial lipoxygenases are known, and no lipoxygenase gene of microbial origin has been described. Su and Oliw, J. Biological Chemistry, 273 (21), 13072-79 (1998) describe a lipoxygenase from *Gaeumannomyces graminis*.  
15

### SUMMARY OF THE INVENTION

The inventors have found a novel fungal lipoxygenase and determined its sequence, which can be used for the production of the enzyme in industrial scale. They have cloned the gene into *E. coli* and deposited the clone.

20 Accordingly, the invention provides a lipoxygenase which is:

a) a polypeptide encoded by a DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139,

b) a polypeptide having an amino acid sequence as the mature peptide shown in SEQ ID NO: 1, or which can be obtained therefrom by substitution, deletion, and/or insertion  
25 of one or more amino acids,

c) an analogue of the polypeptide defined in (a) or (b) which:

i) has at least 50 % homology with said polypeptide,

ii) is immunologically reactive with an antibody raised against said polypeptide in purified form,

30 iii) is an allelic variant of said polypeptide, or

d) a polypeptide encoded by DNA that hybridizes under low stringency conditions with a complementary strand of

i) the DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139 or

35 ii) the DNA sequence of SEQ ID NO: 1 encoding the mature polypeptide or a subsequence thereof having at least 100 nucleotides.

The invention also provides a polynucleotide which comprises:

a) the partial DNA sequence encoding a mature lipoxygenase cloned into a plasmid present in *Escherichia coli* DSM 14139,

b) the partial DNA sequence encoding a mature lipoxygenase shown in SEQ ID NO: 1,

c) an analogue of the sequence defined in a) or b) which encodes a lipoxygenase and

i) has at least 60 % homology with said DNA sequence, or

ii) hybridizes at high stringency with a complementary strand of said DNA sequence or a subsequence thereof having at least 100 nucleotides,

iii) is an allelic variant thereof, or

d) a complementary strand of a), b) or c).

Other aspects of the invention provide a nucleic acid construct and a recombinant expression vector comprising the polynucleotide, a recombinant host cell comprising the construct or the vector, and a method of producing a lipoxygenase by cultivating the cell. Further, the invention provides a method of screening a eukaryotic library to obtain a lipoxygenase and an oligonucleotides probe useful for screening. Finally, the invention provides use of the lipoxygenase in baking and in a detergent.

## DETAILED DESCRIPTION OF THE INVENTION

### Genomic DNA source

A lipoxygenase gene of the invention may be derived from a filamentous fungus, e.g. an Ascomycota, particularly Magnaporthaceae, such as a strain of *Magnaporthe*, particularly *Magnaporthe salvinii* Cattaneo (*Mycologia* 64 (1), 110 (1972)). The species is also known under the synonyms *Curvularia sigmoidea*, *Helminthosporium sigmoideum*, *Leptosphaeria salvinii*, *Nakataea sigmoidea*, *Sclerotium oryzae* and *Vakrabeeja sigmoidea*. An example is the strain *M. salvinii* IFO 6642.

Alternatively, the gene may be isolated from *Pyricularia*, e.g. *P. oryzae* or *P. grisea*, e.g. *P. oryzae* IFO 30517. The IFO strains are available on commercial terms from Institute for Fermentation, Osaka (IFO), 17-85, Juso-honmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan.

The lipoxygenase gene may be isolated from these organisms using probes designed on the basis of the DNA sequences in this specification.

A strain of *Escherichia coli* containing a lipoxygenase gene from *M. salvinii* IFO 6642 was deposited by the inventors under the terms of the Budapest Treaty with the DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig DE, Germany. The deposit date was 28 February 2001, and the accession number was DSM 14139.

## Production of lipoxygenase by cultivation of transformant

The lipoxygenase of the invention may be produced by transforming a suitable host cell with a DNA sequence encoding the lipoxygenase, cultivating the transformed organism under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

The host organism may be a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, e.g. a strain of *Aspergillus*, *Fusarium*, *Trichoderma* or *Saccharomyces*, particularly *A. niger*, *A. oryzae*, *F. graminearum*, *F. sambucinum*, *F. cerealis* or *S. cerevisiae*. The production of the lipoxygenase in such host organisms may be done by the general methods described in EP 238,023 (Novo Nordisk), WO 96/00787 (Novo Nordisk) or EP 244,234 (Alko).

## Properties of LOX

The lipoxygenase of the invention is able to oxidize a wide range of substrates containing a *cis-cis*-pentadienyl moiety. Thus, it acts on polyunsaturated fatty acids such as linoleic acid (18 carbon atoms, 2 double bonds), linolenic acid (18:3), arachidonic acid (20:4), eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6). It also acts on substrates other than fatty acids, such as methyl linoleate and probably also triglycerides. The enzyme has a very low Michaelis constant ( $K_M$ ) for linoleic acid and a high specificity ( $V_{max}/K_M$ ) towards this substrate.

The lipoxygenase from *M. salvinii* is a 9-lipoxygenase, i.e. it oxidizes the double bond between carbon atoms 9 and 10 in linoleic acid and linolenic acid.

The lipoxygenase from *M. salvinii* has optimum activity around pH 7, and it is highly active over a broad pH range 3-12, having more than 50 % of optimum activity in the range pH 6-11. It is stable after overnight incubation at pH 5-11.

The native lipoxygenase from *M. salvinii* has optimum activity at 50-60°C. It is quite active at 40-60°C, and the activity begins to decline at 70 °C. The lipoxygenase is stable after 30 minutes incubation at pH 7 at temperatures up to 50°C.

The reaction rate for recombinant lipoxygenase (expressed in *A. oryzae*) increases nearly ten times at the optimal temperature for catalysis compared to the rate obtained at room temperature. The maximum reaction rate is obtained at 67.5°C. A steep decrease in rate constant is seen above the temperature optimum. It is believed that glycosylation renders the recombinant enzyme more stable towards heat than the wild-type enzyme.

The recombinant lipoxygenase is quite stable at temperatures up to 50°C for at least one hour. The activity drops in a linear fashion at higher temperatures between 50-60°C, and no activity is detected after incubations above 60°C for one hour. No activity loss is detected during incubation at temperatures below 45°C.

Frozen solutions of the lipoxygenase lose some activity during storage. With addition of 10 % glycerol there is no discernible activity loss after two weeks storage at -20°C, and the enzyme survived repeated cycles of thaw-freeze without loss of activity.

The lipoxygenase of the invention has good stability in the presence of anionic surfactants. Thus, the lipoxygenase from *M. salvinii* is stable in the presence of 400 ppm of LAS (linear alkyl-benzene sulfonate).

### Use of lipoxygenase

The lipoxygenase can be used for green flavor synthesis, e.g. nonenal from 9-hydroperoxide of linolenic acid. The synthesis may be done in analogy with Whitehead et al.1995, Cereal foods world 40(4), 193-197 and US 4769243.

The lipoxygenase can also be used for plant hormone synthesis as described in JP H11-29410.

Also the lipoxygenase is a good oxidant of carotenoids, so it can be used for bleaching of foodstuffs such as flour, oil or marine food including carotenoids or carotenoid-like pigments.

The oxidation activity can be utilized for cross-linking of protein, oil, starch, fiber and mixture of these. Cross-linking of chemical compounds can be utilized for synthesis of polymer to give plastic fiber or plastic resin. It can be used for bleaching as a detergent for phenolic, carotenoid or fatty stains or dinginess. Or it can be used for bleaching of waste water or textile dye.

Lipoxygenase can be used for bleaching of plant or marine food materials containing of carotenoids. Thus it could be used for bleaching of flour for bread, noodle or pasta, or bleaching of fish meat or fish oil containing astaxanthin.

It also can be used for cross-linking of protein, oil, starch, plant-fiber or mixture of these in presence of fatty acid, oil or fats. It is useful to change the texture or physical properties of foodstuff or to control of flavor for fat and oil, or to produce polymers made of natural stuff beside food use. Cross-linked compounds can be chemical compounds, e.g. phenolic, carbonyl, carboxyl or amide compounds or mixture of these. It could be used for synthesis of plastic fiber or resin.

Other usages of lipoxygenase can be the synthesis of flavor compound such as hexanal or hexenal together as synergy effect of hydroperoxide lyase. Or in case plant material is used as the source of above two enzymes, lipoxygenase can be added to it to improve the yield of flavor compound. The similar can be done for synthesis of plant or animal hormones.

Finally it can be used as bleaching agent. It can be used in detergents for bleaching of phenolic, carotenoid, fatty stains or dinginess of clothes. Or it can be used for bleaching of textile dye or dye for pulp industry in waste water or changing of dye texture.

**Recombinant expression vector**

The expression vector of the invention typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a selectable marker, a transcription terminator, a repressor gene or various activator genes. The vector may be an autonomously replicating vector, or it may be integrated into the host cell genome.

**Production by cultivation of transformant**

The lipoxxygenase of the invention may be produced by transforming a suitable host cell with a DNA sequence encoding the lipoxxygenase, cultivating the transformed organism under conditions permitting the production of the enzyme, and recovering the enzyme from the culture.

The host organism may be a eukaryotic cell, in particular a fungal cell, such as a yeast cell or a filamentous fungal cell, e.g. a strain of *Aspergillus*, *Fusarium*, *Trichoderma* or *Saccharomyces*, particularly *A. niger*, *A. oryzae*, *F. graminearum*, *F. sambucinum*, *F. cerealis* or *S. cerevisiae*. The production of the lipoxxygenase in such host organisms may be done by the general methods described in EP 238,023 (Novo Nordisk), WO 96/00787 (Novo Nordisk) or EP 244,234 (Alko).

The enzyme can be purified in one step by cation-exchange chromatography to homogeneity.

**Nucleotide probe**

A nucleotide probe may be designed on the basis of the DNA sequence of SEQ ID NO: 1 or the polypeptide sequence of SEQ ID NO: 2, particularly the mature peptide part. The probe may be used in screening for LOX-encoding DNA as described below.

A synthetic oligonucleotide primer may be prepared by standard techniques (e.g. as described in Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual (2<sup>nd</sup> edn.) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) on the basis of the mature part of the amino acid sequence in SEQ ID NO: 2 or the corresponding part of the DNA sequence. It may be a degenerate probe and will typically contain at least 20 nucleotides.

**Screening of eukaryotic DNA library**

A polypeptide with lipoxxygenase activity may be obtained by a method comprising:  
a) preparing a eukaryotic DNA library,  
b) screening the library to select DNA molecules which hybridize to the probe described above,

- c) transforming host cells with the selected DNA molecules,
- d) cultivating the transformed host cells to express polypeptides encoded by the DNA molecules, and
- e) assaying the expressed polypeptides to select polypeptides having lipoxxygenase activity.

The eukaryotic DNA library may be prepared by conventional methods. It may include genomic DNA or double-stranded cDNA derived from suitable sources such as those described above.

Molecular screening for DNA sequences may be carried out by polymerase chain reaction (PCR) followed by hybridization.

In accordance with well-known procedures, the PCR fragment generated in the molecular screening may be isolated and subcloned into a suitable vector. The PCR fragment may be used for screening DNA libraries by e.g. colony or plaque hybridization.

## Hybridization

The hybridization is used to indicate that a given DNA sequence is analogous to a nucleotide probe corresponding to a DNA sequence of the invention. The hybridization may be done at low, medium or high stringency. One example of hybridization conditions is described in detail below.

Suitable conditions for determining hybridization between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA in 5 x SSC (standard saline citrate) for 10 min, and prehybridization of the filter in a solution of 5 x SSC (Sambrook et al. 1989), 5 x Denhardt's solution (Sambrook et al. 1989), 0.5 % SDS and 100 µg/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) *Anal. Biochem.* 132:6-13), <sup>32</sup>P-dCTP-labeled (specific activity > 1 x 10<sup>9</sup> cpm/µg ) probe for 12 hours at approx. 45°C. The filter is then washed two times for 30 minutes in 2 x SSC, 0.5 % SDS at a temperature of at least 55°C, particularly at least 60°C, more particularly at least 65°C, e.g. at least 70°C, or at least 75°C.

Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using an x-ray film.

## Alignment and homology

The lipoxxygenase and the nucleotide sequence of the invention may have homologies to the disclosed sequences of at least 75 % or at least 85 %, particularly at least 90 % or at least 95 %, e.g. at least 98 %.

For purposes of the present invention, alignments of sequences and calculation of

homology scores were done using a Needleman-Wunsch alignment (i.e. global alignment), useful for both protein and DNA alignments. The default scoring matrices BLOSUM50 and the identity matrix are used for protein and DNA alignments respectively. The penalty for the first residue in a gap is -12 for proteins and -16 for DNA, while the penalty for additional residues in a gap is -2 for proteins and -4 for DNA. Alignment is from the FASTA package version v20u6 (W. R. Pearson and D. J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods in Enzymology, 183:63-98).

## EXAMPLES

### Materials and Methods

Molecular cloning techniques are described in Sambrook et al. (1989).

The following commercial plasmids and *E. coli* strains were used for sub-cloning and DNA library construction:

pT7Blue (Novagen)

pUC19 (TOYOBO, Japan)

*E. coli* JM109 (TOYOBO, Japan)

*E. coli* DH12S (GIBCO BRL, Life Technologies, USA)

Labeling and detection of hybridization probe was done using DIG-labeling and detection Kit (Boehringer Mannheim). Nylon membrane Hybond-N+ (Amersham, England) was used for DNA transfer for colony hybridization.

Soybean lipoxygenase (type I-B) (cat.# L7315) and astaxanthin (cat.# A-9335) was supplied by Sigma. b-carotene (cat.# 031-05533) were supplied by Wako.

### Media and buffer solution

COVE-ar: per liter 342.3 g sucrose, 20 ml COVE salt solution, 10 mM acryl amide, 15 mM CsCl<sub>2</sub>, 30 g Agar noble (Difco)

COVE2-ar: per liter 30 g sucrose, 20 ml COVE salt solution, 10 mM acrylamide, 30 g Agar noble (Difco)

COVE salt solution: per liter 26 g KCl, 26 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 76 g KH<sub>2</sub>PO<sub>4</sub>, 50ml Cove trace metals.

Cove trace metals: per liter 0.04 g NaB<sub>4</sub>O<sub>7</sub>·10H<sub>2</sub>O, 0.4 g CuSO<sub>4</sub>·5H<sub>2</sub>O, 1.2 g FeSO<sub>4</sub>·7H<sub>2</sub>O, 0.7 g MnSO<sub>4</sub>·H<sub>2</sub>O, 0.7 g Na<sub>2</sub>MoO<sub>2</sub>·2H<sub>2</sub>O, 0.7 g ZnSO<sub>4</sub>·7H<sub>2</sub>O.

AMG trace metals: per liter 14.3 g ZnSO<sub>4</sub>·7H<sub>2</sub>O, 2.5 g CuSO<sub>4</sub>·5H<sub>2</sub>O, 0.5 g NiCl<sub>2</sub>, 13.8 g FeSO<sub>4</sub>, 8.5 g MnSO<sub>4</sub>, 3.0 g citric acid.

YPG: per liter 4 g yeast extract, 1 g KH<sub>2</sub>PO<sub>4</sub>, 0.5 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 15 g glucose, pH 6.0.



STC: 0.8 M Sorbitol, 25 mM Tris pH 8, 25 mM CaCl<sub>2</sub>.

STPC: 40% PEG4000 in STC buffer.

Cove top agarose: per liter 342.3 g sucrose, 20 ml COVE salt solution, 10 mM Acetamide, 10 g low melt agarose.

5 MS-9: per liter 30 g soybean powder, 20 g glycerol, pH 6.0.

MDU-2Bp: per liter 45 g maltose-1H<sub>2</sub>O, 7 g yeast extract, 12 g KH<sub>2</sub>PO<sub>4</sub>, 1 g MgSO<sub>4</sub>-7H<sub>2</sub>O, 2 g K<sub>2</sub>SO<sub>4</sub>, 5 g Urea, 1 g NaCl, 0.5 ml AMG trace metal solution pH 5.0.

#### Host organism

10 *Aspergillus oryzae* BECh2 is described in WO 00/39322. It is a mutant of JaL228 (described in WO98/123000), which is a mutant of IFO4177.

#### Transformation of *A. oryzae*

*Aspergillus oryzae* strain BECh2 was inoculated in 100 ml of YPG medium and incubated at 32°C for 16 hours with stirring at 80 rpm. Grown mycelia was collected by filtration followed by washing with 0.6 M KCl and re-suspended in 30 ml of 0.6 M KCl containing Glucanex® (Novozymes) at the concentration of 30 µl/ml. The mixture was incubated at 32°C with the agitation at 60 rpm until protoplasts were formed. After filtration to remove the remained mycelia, protoplasts were collected by centrifugation and washed with STC buffer twice. The protoplasts were counted with a hematology and re-suspended in a solution of STC:STPC:DMSO (8:2:0.1) to a final concentration of 1.2 x 10<sup>7</sup> protoplasts/ml. About 4 µg of DNA was added to 100 µl of protoplast solution, mixed gently and incubated on ice for 30 minutes. 1 µl STPC buffer was added to the mixture and incubated at 37°C for another 30 minutes. After the addition of 10 ml of Cove top agarose pre-warmed at 50°C, the reaction mixture was poured onto COVE-ar agar plates. The plates were incubated at 32°C for 5 days.

#### SDS-PAGE

SDS polyacrylamide electrophoresis was carried out using the commercialized gel PAGEL AE6000 NPU-7.5L (7.5T%) with the apparatus AE-6400 (Atto, Japan) following the provided protocol. 15 µl of sample was suspended in 15 µl of 2x conc. of sample loading buffer (100 mM Tris-HCl (pH 6.8), 200 mM Dithiothreitol, 4% SDS, 0.2% Bromophenol blue and 20% glycerol) and boiled for 5 minutes. 20 µl of sample solution was applied to a polyacrylamide gel, and subjected for electrophoresis in the running buffer (25 mM Tris, 0.1% SDS, 192 mM Glycine) at 20 mA per gel. Resulting gel was stained with SYPRO Orange and detected by molecular Imager FX (BIO-RAD).

Assays for lipoxygenase activitySpectrophotometric assay

Lipoxygenase activity was determined spectrophotometrically at 25°C by following the formation of hydroperoxides with the absorbance at 234 nm. To 0.98 ml of the buffer (50 mM  $\text{KH}_2\text{PO}_4/\text{NaHPO}_4$ , pH 7.0), 10  $\mu\text{l}$  of substrate solution (10mM linolenic acid dispersed with 0.2% Tween20) was added and the reaction was started by the addition of 10  $\mu\text{l}$  of enzyme solution. One unit causes an increase in absorbance at 234 nm of 0.001/min.

FOX assay

The assay was initiated by the addition of 20  $\mu\text{l}$  enzyme solution to 80  $\mu\text{l}$  of 50 mM each buffer containing 0.7 mM linolenic acid dispersed with 0.02% of Tween 20 using Hisco-tron, and incubated for 10 min. The assay was terminated by the addition of 900  $\mu\text{l}$  of FOX reagent: sulfuric acid (25 mM), xylenol orange(100  $\mu\text{M}$ ), iron(II) sulfate (100  $\mu\text{M}$ ), butylated hydroxytoluen (4 mM) in methanol:water (9:1). Blanks contained only substrate solution during the incubation, but enzyme solution was added after the addition of FOX reagent. The yellow color of acidified xylenol orange was converted to a blue color by the lipid hydroperoxide-mediated oxidation of  $\text{Fe}^{2+}$  ions with the dye. Absorbance of the  $\text{Fe}^{3+}$  complex at 620 nm was measured 1 hour after the addition of FOX reagent.

Bleaching assay

Bleaching effect by lipoxygenase was examined spectrophotometrically at 25°C by following the absorbance at 470 nm. The pigment solution was prepared as follows. 150  $\mu\text{l}$  of stock pigment solution (1mg each pigment in 1ml chloroform) was evaporated to be dry. Then 30 ml of the buffer (50 mM  $\text{KH}_2\text{PO}_4/\text{NaHPO}_4$ , pH 7.0) with 0.3% of Tween 20 was added slowly and the pigment was dissolved. To 0.98 ml of the pigment solution, 10  $\mu\text{l}$  of substrate solution (10mM linolenic acid dispersed with 0.2% of Tween20) was added and the reaction was started by the addition of 10  $\mu\text{l}$  of enzyme solution.

**Example 1: Cloning of genomic LOX gene from *M. salvinii***

Genomic DNA from *Magnaporthe salvinii* was digested with *Sac I* and separated on 1.0% agarose gel. Around 2.5 kbp of DNA digestion was recovered from the gel and ligated with BAP treated pUC19 linearized by *Sac I*. Ligation mixture was transformed into *E. coli* DH12S to construct a partial genomic library. It was screened, and a lipoxygenase-positive *E. coli* colony was isolated and the plasmid, termed pSG28, was recovered. The plasmid pSG28 contained a 2.5 kbp *SacI* genomic fragment that contained the presumed LOX homologue sequence. The sequence of 1973 bp out of 2.5 kbp is shown as SEQ. ID 1.

Introns were identified and are indicated in SEQ ID NO: 1. The splice sites were pre-

dicted as described in S.M. Hebsgaard et al., Nucleic Acids Research, 1996, Vol. 24, No. 17, 3439-3452.

The presumed open reading frame consisted of 1851 bp, and the deduced amino acid sequence corresponded to 617 amino acids, shown as SEQ ID NO: 2. The molecular mass was estimated as 67500 Da.

The *E. coli* DH12S harboring plasmid pSG28 was deposited at DSMZ as DSM 14139 with the accession date 2001-02-28.

## Example 2: Expression of *M. salvinii* LOX in *A. oryzae*

### Construction of expression plasmid

The partial genomic sequence of *M. salvinii* genomic gene was amplified by PCR using pSG28 as a template. Primer 3 and 4 (SEQ ID NO: 3 and 4) were designed to make *Bam*H I and *Xho* I sites at both ends of the PCR product (nucleotides 4-9 of primer 3 and 5-10 of primer 4, respectively). PCR reaction mixture comprised of 2.5 mM dNTP, 30 pmol each of primer 3 and 4, 5 units of LA taq polymerase (Takara) and supplied GC buffer I. Reaction condition was shown below. LA taq polymerase was added to the reaction mixture after step 1.

Step	Temperature	Time
1	98 °C	10 mins
2	96 °C	20 sec
3	55 °C	45 sec
4	72 °C	30 sec
5	72 °C	10 mins

\* Step 2 to Step 4 were repeated 30 times.

PCR amplified 1.9 kb fragment was isolated and cloned into pT7Blue resulting in pSG29.

The plasmid pSG29 was digested by *Bam*HII and *Xho*I and 1.9 kb of fragment which contained the LOX gene was ligated with pMT2188 digested with *Bam*HI and *Xho*I. The plasmid pMT2188 has a modified *Aspergillus niger* neutral amylase promoter, *Aspergillus nidulans* TPI leader sequence, *Aspergillus niger* glucoamylase terminator, *Aspergillus nidulans* amdS gene as a marker for fungal transformation and *S. cerevisiae* ura3 as the marker for *E. coli* transformation. Transformation was done with *E. coli* DB6507 in which pyrF gene is deficient and can be complemented with *S. cerevisiae* Ura3. Resulting plasmid was termed pSG30.

Expression of *M. salvinii* LOX in *A. oryzae*

*A. oryzae* BECh2 was transformed with the plasmid pSG30 and selection positive transformants were isolated. Transformants were grown on COVE 2 -ar at 32°C for 5 days and inoculated to 100 ml of MS-9 shaking flask. After the cultivation with vigorous agitation at 32°C for 1 day, 3 ml of each culture was transferred to 100 ml of MDU-2Bp in shaking flask to cultivate at 32°C for 3 days. Culture broth was centrifuged at 3500 rpm for 10 minutes and supernatant was collected.

Lipoxygenase activities of the supernatant were determined spectrophotometrically as described before. Positive transformants showed about 100,000U/ml culture broth while untransformed *A. oryzae* BECh2 showed no activity. Culture supernatant was also subjected to SDS-PAGE analysis. Positive transformants showed 80-100kDa smear band which indicated the protein was heavily glycosylated. Untransformed *A. oryzae* BECh2 did not show any significant bands.

**Example 3: Substrate specificity of lipoxygenase**

Kinetic parameters for a number of substrates were determined by standard methods for the *M. salvinii* lipoxygenase.

Substrate	$V_{max}$ ( $\mu\text{mol}/\text{min}/\text{mg}$ )	$K_M$ ( $\mu\text{M}$ )	$V_{max}/K_M$ ( $\mu\text{mol}/\text{min}/\text{mg}/\mu\text{M}$ )
Linoleic acid	2.63	1	2.557
Na linoleate	2.07	0.41	5.061
Linoelaidic acid	No activity	No activity	No activity
Linolenic acid	1.9	0.4	4.488
Eicosadienoic acid	2.02	11	0.177
Arachidonic acid	2.44	5.5	0.446
Linoleoyl chloride	0.97	12	0.080
Methyl linoleate	0.82	30	0.026
Linoleoyl acetate	0.77	9	0.085
Linoleoyl alcohol	1.4	8	0.175

For comparison, one substrate was also tested with soybean lipoxygenase.

Substrate	$V_{\max}$ ( $\mu\text{mol}/\text{min}/\text{mg}$ )	$K_M$ ( $\mu\text{M}$ )	$V_{\max}/K_M$ ( $\mu\text{mol}/\text{min}/\text{mg}/\mu\text{M}$ )
Linoleic acid	12.3	230	0.054

### Example 3: pH dependence of lipoxygenase activity

5           The relative activity of the *M. salvinii* lipoxygenase at various pH values was determined by the FOX assay described above, using the following buffers: 50 mM citric acid/sodium citrate (pH 2.21-3.73) ,  $\text{KH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$  (pH 5.30,6.17), Tris/HCl (pH 7.01,8.02), glycylglycine NaCl/NaOH (pH 9.33-11.0).

pH	Relative Activity (%)
2.21	7.11
2.90	20.6
3.73	27.7
5.30	60.0
6.17	83.7
7.01	100
8.02	92.9
9.33	82.6
11.0	77.7

10

### Example 4: Temperature dependence of lipoxygenase activity

The effect of temperature on the *M. salvinii* lipoxygenase was studied by 10 min incubation at pH 7.0.

15

Temperature	Relative Activity (%)
25	50.1
40	90.0
50	100
60	99.6
70	60.4

**Example 5: Bleaching effect of lipoxygenases**

The bleaching effect of *M. salvinii* LOX was examined. Soybean L1 was included for comparison.  $\beta$ -carotene and astaxanthin were used as pigments.

$\beta$ -carotene	Time (min)	<i>M. salvinii</i>	Soybean L1
	0	0.3783	0.3575
	0.4	0.3791	0.3616
	0.8	0.3729	0.3601
	1.2	0.3702	0.362
	1.4	0.3685	0.3602
	1.8	0.3651	0.3602
	2.2	0.3633	0.3595
	2.6	0.3486	0.3595
	3	0.341	0.3594
$\Delta A_{470}/\text{min}$		0.0121	0.00005
LOX activity		2.652	1.962

5

Astaxanthin	Time (min.)	<i>M. salvinii</i>	Soybean L1
	0	0.5292	0.5026
	0.4	0.5244	0.5029
	0.8	0.5177	0.505
	1	0.5166	0.5025
	1.4	0.512	0.5013
	1.8	0.5004	0.4993
	2.2	0.4876	0.4985
	2.6	0.4714	0.4986


	3	0.4566	0.498
$\Delta A_{470}/\text{min}$		0.0239	0.0021
<b>LOX activity</b>		2.4952	2.018

The results show that *M. salvinii* LOX bleaches the pigment solutions. Soybean LOX showed little effect on bleaching.

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.92 (updated 01.01.2002)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	10148

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	2
1-2	line	36-37
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Mascheroder Weg 1b, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	28 February 2001 (28.02.2001)
1-3-4	Accession Number	DSMZ 14139
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications  These indications will be submitted to the International Bureau later	NONE

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	YES
0-4-1	Authorized officer	 Marie Louise Rosendal Head Clerk

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	



**CLAIMS**

1. A lipoxygenase which is:

a) a polypeptide encoded by a DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139,

b) a polypeptide having an amino acid sequence as the mature peptide shown in SEQ ID NO: 1, or which can be obtained therefrom by substitution, deletion, and/or insertion of one or more amino acids,

c) an analogue of the polypeptide defined in (a) or (b) which:

i) has at least 50 % homology with said polypeptide,

ii) is immunologically reactive with an antibody raised against said polypeptide in purified form,

iii) is an allelic variant of said polypeptide, or

d) a polypeptide encoded by DNA that hybridizes under low stringency conditions with a complementary strand of

i) the DNA sequence cloned into plasmid pUC19 present in *Escherichia coli* deposited as DSM 14139 or

ii) the DNA sequence of SEQ ID NO: 1 encoding the mature polypeptide or a subsequence thereof having at least 100 nucleotides.

2. The lipoxygenase of claim 1 which is derived from a filamentous fungus, e.g. an Ascomycota, such as a strain of *Magnaporthe*, particularly *M. salvinii*, more particularly strain IFO 6642.

3. DNA comprising a nucleic acid sequence which encodes the lipoxygenase of claim 1 or 2.

4. A polynucleotide which comprises:

a) the partial DNA sequence encoding a mature lipoxygenase cloned into a plasmid present in *Escherichia coli* DSM 14139,

b) the partial DNA sequence encoding a mature lipoxygenase shown in SEQ ID NO: 1,

c) an analogue of the sequence defined in a) or b) which encodes a lipoxygenase and

i) has at least 60 % homology with said DNA sequence, or

ii) hybridizes at high stringency with a complementary strand of said DNA sequence or a subsequence thereof having at least 100 nucleotides,

iii) is an allelic variant thereof, or

d) a complementary strand of a), b) or c).

5. A nucleic acid construct comprising the nucleic acid sequence of claim 3 or 4 operably linked to one or more control sequences capable of directing the expression of the lipoxygenase in a suitable expression host.

5 6. A recombinant expression vector comprising the nucleic acid construct of claim 5, a promoter, and transcriptional and translational stop signals.

7. A recombinant host cell comprising the nucleic acid construct of claim 5 or the vector of claim 6.

10

8. A method for producing a lipoxygenase comprising cultivating the host cell of claim 7 under conditions conducive to production of the lipoxygenase, and recovering the lipoxygenase.

15 9. An oligonucleotide probe which consists of at least 20 nucleotides and which encodes a partial polypeptide sequence of SEQ ID NO: 2.

10. A method for obtaining a polypeptide with lipoxygenase activity, comprising:

- 20 a) preparing a eukaryotic DNA library,  
b) screening the library to select DNA molecules which hybridize to the probe of claim 9,  
c) transforming host cells with the selected DNA molecules,  
d) cultivating the transformed host cells to express polypeptides encoded by the DNA molecules, and  
e) assaying the expressed polypeptides to select polypeptides having lipoxygenase activity.
- 25

11. A method for preparing a dough or a baked product made from dough, comprising adding the lipoxygenase of claim 1 or 2 to the dough.

30 12. A dough composition comprising the lipoxygenase of claim 1 or 2.

13. A detergent composition comprising a surfactant and the lipoxygenase of claim 1 or 2.

14. The detergent composition of the preceding claim wherein the surfactant is anionic.

35

15. A process for oxidizing a polyunsaturated fatty acid comprising contacting the acid with the lipoxygenase of claim 1 or 2 in the presence of air.

16. Use of the process of the preceding claim for green flavor synthesis or plant hormone synthesis.

10148-WO.ST25  
SEQUENCE LISTING

<110> Novozymes A/S

<120> Lipoxygenase

<130> 10148-wo

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 1973

<212> DNA

<213> Magnaporthe salvinii

<220>

<221> CDS

<222> (1)..(381)

<223>

<220>

<221> mat\_peptide

<222> (52)..()

<223>

<220>

<221> CDS

<222> (501)..(1970)

<223>

<400> 1  
atg cgc atc gga ctc ttg gcc ttc gcc gtc gcg gcg cgc tat gtg gaa  
Met Arg Ile Gly Leu Leu Ala Phe Ala Val Ala Ala Arg Tyr Val Glu  
-15 -10 -5

48

## 10148-WO.ST25

gcg	ctg	cca	gtc	gcg	agc	ggc	gaa	gaa	gtg	gcc	tcg	tcg	tcc	gct	ccg	96
Ala	Leu	Pro	Val	Ala	Ser	Gly	Glu	Glu	Val	Ala	Ser	Ser	Ser	Ala	Pro	
-1	1				5					10					15	
acg	acg	ctg	ccc	tcg	acg	tcg	agc	agc	tct	gcg	ctt	ccc	tcc	ccg	acc	144
Thr	Thr	Leu	Pro	Ser	Thr	Ser	Ser	Ser	Ser	Ala	Leu	Pro	Ser	Pro	Thr	
				20					25					30		
aag	tac	acg	ctt	ccc	cac	gag	gac	ccc	aac	ccg	gaa	gcg	agg	aag	gcc	192
Lys	Tyr	Thr	Leu	Pro	His	Glu	Asp	Pro	Asn	Pro	Glu	Ala	Arg	Lys	Ala	
			35					40					45			
gag	ata	gcg	tta	aag	agg	gga	ggg	ttc	ctc	tac	gga	ccc	tcc	acc	ctg	240
Glu	Ile	Ala	Leu	Lys	Arg	Gly	Gly	Phe	Leu	Tyr	Gly	Pro	Ser	Thr	Leu	
		50				55					60					
ggc	cag	act	acc	ttt	tac	ccc	agc	ggg	acc	ctg	ggg	acc	gcc	atg	tcg	288
Gly	Gln	Thr	Thr	Phe	Tyr	Pro	Ser	Gly	Thr	Leu	Gly	Thr	Ala	Met	Ser	
	65					70					75					
caa	cgc	gac	cag	gcc	ctc	tgg	ctc	agg	gat	gca	gag	aac	caa	acg	ata	336
Gln	Arg	Asp	Gln	Ala	Leu	Trp	Leu	Arg	Asp	Ala	Glu	Asn	Gln	Thr	Ile	
80					85					90					95	
aca	gcg	tat	cgt	gaa	gcc	aac	gag	aca	ctg	agg	gat	atc	cag	agc		381
Thr	Ala	Tyr	Arg	Glu	Ala	Asn	Glu	Thr	Leu	Arg	Asp	Ile	Gln	Ser		
				100					105					110		
gtatgtgtcg	agccgtgttt	atgcgtttcca	atcattctct	gtgctcctgt	ccgtccccgc											441
ccgggggttac	agccaagccg	attcagtagc	taactcggaa	tgtctggttt	gctctgcag											500
cat	ggc	ggt	ctc	aag	acg	ctt	gac	gac	ttc	gcg	ctc	ctc	tac	gac	ggc	548
His	Gly	Gly	Leu	Lys	Thr	Leu	Asp	Asp	Phe	Ala	Leu	Leu	Tyr	Asp	Gly	
				115					120					125		
cat	tgg	aaa	gcg	tcg	gtc	cca	gag	gga	ata	gaa	aag	ggc	atg	ctg	agc	596
His	Trp	Lys	Ala	Ser	Val	Pro	Glu	Gly	Ile	Glu	Lys	Gly	Met	Leu	Ser	
			130				135						140			
aac	tac	act	tcg	gac	ctg	ctc	ttt	tcc	atg	gag	cgg	ctc	tcc	aac	aac	644
Asn	Tyr	Thr	Ser	Asp	Leu	Leu	Phe	Ser	Met	Glu	Arg	Leu	Ser	Asn	Asn	
		145					150					155				
ccc	tac	agc	ctc	aag	cgc	ctc	cat	cca	acc	aag	gac	aag	ctg	ccg	ttc	692
Pro	Tyr	Ser	Leu	Lys	Arg	Leu	His	Pro	Thr	Lys	Asp	Lys	Leu	Pro	Phe	
	160					165					170					
agc	gtc	gag	gac	aag	gtg	gtc	aag	cag	ctg	acg	gcc	acg	acg	ctt	gcg	740
Ser	Val	Glu	Asp	Lys	Val	Val	Lys	Gln	Leu	Thr	Ala	Thr	Thr	Leu	Ala	
175					180					185					190	
gcg	ctc	cac	aag	gcc	ggc	cgt	ctc	ttc	ttc	gtt	gac	cac	agc	gat	cag	788
Ala	Leu	His	Lys	Ala	Gly	Arg	Leu	Phe	Phe	Val	Asp	His	Ser	Asp	Gln	
				195				200						205		
aag	aaa	tac	acg	ccg	cag	gca	ggt	cgg	tat	gct	gcg	gcc	tgc	cag	ggg	836
Lys	Lys	Tyr	Thr	Pro	Gln	Ala	Gly	Arg	Tyr	Ala	Ala	Ala	Cys	Gln	Gly	
			210					215					220			
ctt	ttc	tat	gtg	gac	gcg	cgg	tcc	aat	cag	ttc	ctg	ccg	ctg	gcc	atc	884
Leu	Phe	Tyr	Val	Asp	Ala	Arg	Ser	Asn	Gln	Phe	Leu	Pro	Leu	Ala	Ile	
		225					230					235				
aag	acc	aac	gtg	ggc	gca	gac	ctg	acg	tac	acg	cca	ctc	gac	gac	aag	932
Lys	Thr	Asn	Val	Gly	Ala	Asp	Leu	Thr	Tyr	Thr	Pro	Leu	Asp	Asp	Lys	
	240					245					250					

## 10148-WO.ST25

aac Asn 255	gac Asp	tgg Trp	ctt Leu	ctg Leu	gcc Ala 260	aag Lys	atc Ile	atg Met	ttc Phe	aac Asn 265	aac Asn	aat Asn	gac Asp	ctg Leu	ttc Phe 270	980
tac Tyr	tcg Ser	cag Gln	atg Met	tac Tyr 275	cat His	gtc Val	ctg Leu	ttc Phe	cac His 280	acg Thr	gtt Val	cca Pro	gaa Glu	atc Ile 285	gtg Val	1028
cac His	atg Met	gcc Ala	gcc Ala 290	atc Ile	cgg Arg	acg Thr	cta Leu	agc Ser 295	gag Glu	agc Ser	cac His	ccg Pro	gtg Val 300	ctg Leu	gcc Ala	1076
gtg Val	ctc Leu	aat Asn 305	cgg Arg	atc Ile	atg Met	tat Tyr	caa Gln 310	gcc Ala	tat Tyr	gcg Ala	atc Ile	cgg Arg 315	cca Pro	gtg Val	ggc Gly	1124
gaa Glu 320	cgc Arg	atc Ile	ctg Leu	ttc Phe	aac Asn	ccg Pro 325	ggc Gly	ggg Gly	ttt Phe	tgg Trp	gac Asp 330	cag Gln	aac Asn	ctt Leu	ggc Gly	1172
ctg Leu 335	ccc Pro	gcc Ala	acg Thr	gcg Ala	gcc Ala 340	gtc Val	gac Asp	ttt Phe	ctc Leu	agt Ser 345	tcc Ser	atc Ile	tac Tyr	gcc Ala	cat His 350	1220
ggc Gly	gag Glu	ggc Gly	ggg Gly	ttc Phe 355	cgg Arg	gcc Ala	ggc Gly	tac Tyr	gtg Val 360	gaa Glu	aac Asn	aac Asn	ctg Leu	cgc Arg 365	aag Lys	1268
cgg Arg	ggg Gly	ctg Leu	gtg Val 370	ggc Gly	gac Asp	acc Thr	ttt Phe	ggc Gly 375	ggc Gly	ccg Pro	gcg Ala	ctc Leu	ccg Pro 380	cac His	ttc Phe	1316
ccc Pro	ttc Phe	tac Tyr 385	gag Glu	gac Asp	gcg Ala	cag Gln	cgc Arg 390	gtc Val	ctc Leu	ggg Gly	gcg Ala	atc Ile 395	cgc Arg	ggc Gly	ttc Phe	1364
atg Met	cag Gln 400	gcc Ala	ttt Phe	gtc Val	gac Asp	tcg Ser 405	acc Thr	tac Tyr	ggg Gly	ggc Gly	gac Asp 410	gac Asp	ggc Gly	gcg Ala	ctg Leu	1412
gcg Ala 415	cgc Arg	gac Asp	ttt Phe	gag Glu	ctg Leu 420	cag Gln	gac Asp	tgg Trp	gtg Val	gcc Ala 425	gag Glu	gcc Ala	aac Asn	ggg Gly	ccg Pro 430	1460
gcg Ala	cag Gln	gtg Val	cgc Arg	gac Asp 435	ttc Phe	ccc Pro	acg Thr	gcg Ala	ccg Pro 440	ctg Leu	cgg Arg	cgg Arg	cgc Arg	gag Glu 445	gag Glu	1508
ctg Leu	gtg Val	ggc Gly	atc Ile 450	ctg Leu	acg Thr	cac His	ata Ile	gcc Ala 455	tgg Trp	aac Asn	acg Thr	ggc Gly	ggc Gly 460	gcg Ala	cac His	1556
cac His	gtt Val	cta Leu 465	aac Asn	cag Gln	ggg Gly	gcg Ala	ccc Pro 470	gtg Val	cgc Arg	gcc Ala	tcg Ser	ggc Gly 475	gtg Val	ctg Leu	ccg Pro	1604
ctc Leu 480	cac His	ccg Pro	gcg Ala	gct Ala	ctt Leu	tac Tyr 485	gcg Ala	ccc Pro	gtc Val	ccg Pro	gcg Ala 490	gcc Ala	aag Lys	ggc Gly	gcc Ala	1652
gtc Val 495	gcg Ala	tcc Ser	agc Ser	gac Asp	ggc Gly 500	ctg Leu	ctg Leu	gcg Ala	tgg Trp	ctg Leu 505	ccg Pro	gac Asp	gag Glu	gtc Val	aaa Lys 510	1700
tcg Ser	gtg Val	gag Glu	cag Gln	gtg Val 515	tcg Ser	ctg Leu	ctg Leu	gcg Ala	cgc Arg 520	ttc Phe	aac Asn	cgc Arg	gcg Ala	cag Gln 525	gtt Val	1748

## 10148-WO.ST25

agg gac aga aac cag acg gtg cgc aac atg ttc gcc gca ccg gag ctg	1796
Arg Asp Arg Asn Gln Thr Val Arg Asn Met Phe Ala Ala Pro Glu Leu	
530 535 540	
ctg gct gga aat ggc gag gcg tac gcg gcg gcc aac gcg agg ttc gtc	1844
Leu Ala Gly Asn Gly Glu Ala Tyr Ala Ala Asn Ala Arg Phe Val	
545 550 555	
gag gag acg ggc cgg ata agc cgc gag ata gag ggc agg ggt ttc gat	1892
Glu Glu Thr Gly Arg Ile Ser Arg Glu Ile Glu Gly Arg Gly Phe Asp	
560 565 570	
agc aag ggc ctg agc cag ggg atg ccc ttt atc tgg acc gcc ttg aat	1940
Ser Lys Gly Leu Ser Gln Gly Met Pro Phe Ile Trp Thr Ala Leu Asn	
575 580 585 590	
ccc gcg gtg aac ccg ttt ttc ctg agc atc tag	1973
Pro Ala Val Asn Pro Phe Phe Leu Ser Ile 600	

&lt;210&gt; 2

&lt;211&gt; 617

&lt;212&gt; PRT

&lt;213&gt; Magnaporthe salvinii

&lt;400&gt; 2

Met Arg Ile Gly Leu Leu Ala Phe Ala Val Ala Ala Arg Tyr Val Glu
-15 -10 -5
Ala Leu Pro Val Ala Ser Gly Glu Glu Val Ala Ser Ser Ser Ala Pro
-1 1 5 10 15
Thr Thr Leu Pro Ser Thr Ser Ser Ser Ser Ala Leu Pro Ser Pro Thr
20 25 30
Lys Tyr Thr Leu Pro His Glu Asp Pro Asn Pro Glu Ala Arg Lys Ala
35 40 45
Glu Ile Ala Leu Lys Arg Gly Gly Phe Leu Tyr Gly Pro Ser Thr Leu
50 55 60
Gly Gln Thr Thr Phe Tyr Pro Ser Gly Thr Leu Gly Thr Ala Met Ser
65 70 75
Gln Arg Asp Gln Ala Leu Trp Leu Arg Asp Ala Glu Asn Gln Thr Ile
80 85 90 95
Thr Ala Tyr Arg Glu Ala Asn Glu Thr Leu Arg Asp Ile Gln Ser His
100 105 110
Gly Gly Leu Lys Thr Leu Asp Asp Phe Ala Leu Leu Tyr Asp Gly His
115 120 125

## 10148-WO.ST25

Trp Lys Ala Ser Val Pro Glu Gly Ile Glu Lys Gly Met Leu Ser Asn  
 130 135 140  
 Tyr Thr Ser Asp Leu Leu Phe Ser Met Glu Arg Leu Ser Asn Asn Pro  
 145 150 155  
 Tyr Ser Leu Lys Arg Leu His Pro Thr Lys Asp Lys Leu Pro Phe Ser  
 160 165 170 175  
 Val Glu Asp Lys Val Val Lys Gln Leu Thr Ala Thr Thr Leu Ala Ala  
 180 185 190  
 Leu His Lys Ala Gly Arg Leu Phe Phe Val Asp His Ser Asp Gln Lys  
 195 200 205  
 Lys Tyr Thr Pro Gln Ala Gly Arg Tyr Ala Ala Ala Cys Gln Gly Leu  
 210 215 220  
 Phe Tyr Val Asp Ala Arg Ser Asn Gln Phe Leu Pro Leu Ala Ile Lys  
 225 230 235  
 Thr Asn Val Gly Ala Asp Leu Thr Tyr Thr Pro Leu Asp Asp Lys Asn  
 240 245 250 255  
 Asp Trp Leu Leu Ala Lys Ile Met Phe Asn Asn Asn Asp Leu Phe Tyr  
 260 265 270  
 Ser Gln Met Tyr His Val Leu Phe His Thr Val Pro Glu Ile Val His  
 275 280 285  
 Met Ala Ala Ile Arg Thr Leu Ser Glu Ser His Pro Val Leu Ala Val  
 290 295 300  
 Leu Asn Arg Ile Met Tyr Gln Ala Tyr Ala Ile Arg Pro Val Gly Glu  
 305 310 315  
 Arg Ile Leu Phe Asn Pro Gly Gly Phe Trp Asp Gln Asn Leu Gly Leu  
 320 325 330 335  
 Pro Ala Thr Ala Ala Val Asp Phe Leu Ser Ser Ile Tyr Ala His Gly  
 340 345 350  
 Glu Gly Gly Phe Arg Ala Gly Tyr Val Glu Asn Asn Leu Arg Lys Arg  
 355 360 365  
 Gly Leu Val Gly Asp Thr Phe Gly Gly Pro Ala Leu Pro His Phe Pro  
 370 375 380  
 Phe Tyr Glu Asp Ala Gln Arg Val Leu Gly Ala Ile Arg Gly Phe Met  
 385 390 395



10148-WO.ST25

Gln Ala Phe Val Asp Ser Thr Tyr Gly Gly Asp Asp Gly Ala Leu Ala  
400 405 410 415

Arg Asp Phe Glu Leu Gln Asp Trp Val Ala Glu Ala Asn Gly Pro Ala  
420 425 430

Gln Val Arg Asp Phe Pro Thr Ala Pro Leu Arg Arg Arg Gly Glu Leu  
435 440 445

Val Gly Ile Leu Thr His Ile Ala Trp Asn Thr Gly Gly Ala His His  
450 455 460

Val Leu Asn Gln Gly Ala Pro Val Arg Ala Ser Gly Val Leu Pro Leu  
465 470 475

His Pro Ala Ala Leu Tyr Ala Pro Val Pro Ala Ala Lys Gly Ala Val  
480 485 490 495

Ala Ser Ser Asp Gly Leu Leu Ala Trp Leu Pro Asp Glu Val Lys Ser  
500 505 510

Val Glu Gln Val Ser Leu Leu Ala Arg Phe Asn Arg Ala Gln Val Arg  
515 520 525

Asp Arg Asn Gln Thr Val Arg Asn Met Phe Ala Ala Pro Glu Leu Leu  
530 535 540

Ala Gly Asn Gly Glu Ala Tyr Ala Ala Ala Asn Ala Arg Phe Val Glu  
545 550 555

Glu Thr Gly Arg Ile Ser Arg Glu Ile Glu Gly Arg Gly Phe Asp Ser  
560 565 570 575

Lys Gly Leu Ser Gln Gly Met Pro Phe Ile Trp Thr Ala Leu Asn Pro  
580 585 590

Ala Val Asn Pro Phe Phe Leu Ser Ile  
595 600

<210> 3

<211> 29

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc\_feature

10148-WO.ST25

&lt;223&gt; Artificial

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Primer 3

<400> 3  
cgcggatcca tgcgcatcgg actcttggc

29

&lt;210&gt; 4

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial/Unknown

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Artificial

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Primer 4

<400> 4  
cccgtcgcgag ctagatgctc aggaaaaacg g

31

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 02/00251

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N9/02 A21D8/04 C12P7/64 C12N15/63 C11D3/386		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A21D C12P C11D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) PAJ, EPO-Internal, SEQUENCE SEARCH		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 20730 A (NOVOZYMES AS) 14 March 2002 (2002-03-14) claims 1-17 & DATABASE EBI [Online] retrieved from EBI Database accession no. ax398040 77% identity in 618 aa overlap with SEQ ID No.2	1-8, 10-16
A	--- WO 00 60093 A (INST PFLANZENBIOCHEMIE IPB (DE)) 12 October 2000 (2000-10-12) claims 1-14 --- -/--	1-8, 10-16
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  1 August 2002		Date of mailing of the international search report  15. 08. 2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  ekström nils

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 02/00251

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 07, 29 September 2000 (2000-09-29) & JP 2000 106832 A (HONEN CORP), 18 April 2000 (2000-04-18) abstract; claims 1-5 ---	1-8, 10-16
A	US 6 204 037 B1 (BRASH A R ET AL) 20 March 2001 (2001-03-20) claims 1-22 ---	1-8, 10-16
P,A	WO 01 29227 A (BASF AG) 26 April 2001 (2001-04-26) claims 1-20 ---	1-8, 10-16
P,A	WO 01 79560 A (GLAXO GROUP LTD ;EDWARDS LISA D (US); EMMETT AMANDA H (US); ANDERS) 25 October 2001 (2001-10-25) claims 1-31 ---	1-8, 10-16
P,A	WO 01 90323 A (MILLENNIUM PHARM INC (US)) 29 November 2001 (2001-11-29) claims 1-22 ---	1-8, 10-16
P,A	HÖRNSTEN L ET AL: "Cloning of the manganese lipxygenase gene reveals homology with the lipxygenase gene family." EUR. J. BIOCHEM., vol. 269, 2002, pages 2690-2697, XP002902589 the whole document -----	1-8, 10-16

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 02/00251

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 9  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 9

Claim 9 relates to oligonucleotid consisting of at least 20 nucleotides and encodes a partial polypeptide of SEQ. ID. No. 2. These polypeptides are 601 amino acids long- encoded by more than 1800 nucleotides; claim 9 covers a large number of possibilities. In view of the large number of possibilities- not limited even by a general functionality- render it difficult, if not impossible, to determine the matter for which protection is sought. The present claim fails to comply with the clarity and conciseness requirements of Article 6 PCT to such extent that a meaningful search is impossible. As a consequence of this, claim 9 has not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 02/00251

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0220730	A	14-03-2002	AU 8571901 A WO 0220730 A2	22-03-2002 14-03-2002
WO 0060093	A	12-10-2000	DE 19914464 A1 AU 3557700 A WO 0060093 A1 EP 1165801 A1	05-10-2000 23-10-2000 12-10-2000 02-01-2002
JP 2000106832	A	18-04-2000	NONE	
US 6204037	B1	20-03-2001	US 2001046672 A1	29-11-2001
WO 0129227	A	26-04-2001	DE 19950921 A1 AU 1023501 A WO 0129227 A1 EP 1222282 A1 NO 20021851 A	26-04-2001 30-04-2001 26-04-2001 17-07-2002 03-06-2002
WO 0179560	A	25-10-2001	AU 5166501 A WO 0179560 A2	30-10-2001 25-10-2001
WO 0190323	A	29-11-2001	AU 6475301 A WO 0190323 A2	03-12-2001 29-11-2001